Stock Region Penny Picks
The Stock Region Penny Picks Watchlist - Tuesday, December 2, 2025.
The Stock Region Penny Picks Watchlist - Tuesday, December 2, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The information provided in this newsletter is for informational and entertainment purposes only. It should not be considered as financial or investment advice. The stock market is volatile, and all investments carry risk. The opinions expressed here are our own and do not represent a recommendation to buy or sell any security. Please conduct your own research and consult with a licensed financial advisor before making any investment decisions.
What a day in the markets yesterday. We saw some significant moves and compelling announcements that have definitely reshaped our watchlist. Let’s break down the news that caught our eye and explore what it could mean going forward.
Today’s Top Watchlist Movers
$JSPR - Jasper Therapeutics
Jasper dropped some potentially game-changing news. They reported positive preliminary data from their asthma study on Briquilimab. Biotech can be a wild ride, but positive clinical data is the fuel these stocks run on. While it’s still “preliminary,” this is the kind of update that makes you sit up and pay attention. We’ll be watching to see how the market fully digests this and what the next steps are for their clinical program.
$CAPS - Capstone
This one is interesting. Capstone just closed its acquisition of Canadian Stone Industries, a move that adds a cool $15 million in revenue. Acquisitions can be a powerful growth lever. Capstone isn’t just buying revenue; they’re expanding their footprint across North America. This is a classic expansion play, and we’re keen to see how smoothly they integrate the new business and if it translates to bottom-line growth.
$PLRZ - Polyrizon
Polyrizon announced it hit a key manufacturing milestone for its nasal spray platform. In the pharma world, being able to produce your product at scale is a massive hurdle. Clearing it is a big deal. This signals they are moving from the theoretical to the practical. It’s a de-risking event, and for a company in this sector, that’s exactly what you want to see.
$CAPT - Captivision
Hold on to your hats for this one. Captivision plans to acquire a subsidiary of Montana Goldfields valued at a staggering $750 million. The goal? To create a new, Nasdaq-listed US mining company. This is a massive, transformative deal. It’s ambitious, and the numbers involved are huge. This could be a complete re-rating event for Captivision if they pull it off. We’re watching this one with popcorn in hand.
$NIVF - NewGen
NewGen is flexing its financial strength. They reported their nine-month results, highlighting a strengthened balance sheet with a net asset value of $66.75 per share. In a market that often rewards growth at all costs, seeing a company focus on building a rock-solid balance sheet is refreshing. This kind of financial health provides a strong foundation for future moves.
$ACON - Aclarion
Volume is the lifeblood of a moving stock, and Aclarion saw a 7.42x surge yesterday. The catalyst? They appointed a new Commercial Director to push for market adoption in the Eastern U.S. This is a clear signal that they are shifting gears from development to sales. A new commercial leader combined with a spike in trader interest makes ACON a must-watch.
$BDTX - Black Diamond Therapeutics
Get your calendars ready. Black Diamond is hosting a webcast to present its Phase 2 clinical trial results for Silevertinib. These events are often make-or-break for biotech companies. Positive results can send a stock soaring, while disappointing data can have the opposite effect. This is a major upcoming catalyst that could bring serious volatility.
$FIEE - FiEE, Inc.
FiEE is going global, announcing the acquisition of a Japanese firm to boost its tech capabilities. This looks like a strategic move to not only acquire new technology but also to gain a foothold in the Asian market. International expansion is a bold strategy, and we’ll be watching to see how this new piece fits into their global puzzle.
That’s a wrap for today’s watchlist! It’s a mix of clinical progress, strategic acquisitions, and major financial moves. Stay sharp, do your homework, and let’s see what the market brings us today.
Trade smart,
The Stock Region Team
Final Disclaimer: Investing involves substantial risk of loss and is not suitable for every investor. The content of this newsletter represents our personal opinions and analysis. We are not licensed financial professionals, and you should not construe any information discussed herein as a recommendation to purchase or sell securities. Always perform your own due diligence before making any investment.